CN1261095C - 脑、脊髓和神经损伤治疗方法 - Google Patents

脑、脊髓和神经损伤治疗方法 Download PDF

Info

Publication number
CN1261095C
CN1261095C CNB018037208A CN01803720A CN1261095C CN 1261095 C CN1261095 C CN 1261095C CN B018037208 A CNB018037208 A CN B018037208A CN 01803720 A CN01803720 A CN 01803720A CN 1261095 C CN1261095 C CN 1261095C
Authority
CN
China
Prior art keywords
magnesium
receptor antagonist
brain
purposes
injury
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB018037208A
Other languages
English (en)
Chinese (zh)
Other versions
CN1426302A (zh
Inventor
R·温克
A·J·尼莫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN1426302A publication Critical patent/CN1426302A/zh
Application granted granted Critical
Publication of CN1261095C publication Critical patent/CN1261095C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CNB018037208A 2000-01-18 2001-01-18 脑、脊髓和神经损伤治疗方法 Expired - Fee Related CN1261095C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPQ5146 2000-01-18
AUPQ5146A AUPQ514600A0 (en) 2000-01-18 2000-01-18 Brain injury treatment

Publications (2)

Publication Number Publication Date
CN1426302A CN1426302A (zh) 2003-06-25
CN1261095C true CN1261095C (zh) 2006-06-28

Family

ID=3819274

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB018037208A Expired - Fee Related CN1261095C (zh) 2000-01-18 2001-01-18 脑、脊髓和神经损伤治疗方法

Country Status (20)

Country Link
US (5) US6841551B2 (https=)
EP (1) EP1261335B1 (https=)
JP (1) JP4794794B2 (https=)
KR (1) KR100780119B1 (https=)
CN (1) CN1261095C (https=)
AU (2) AUPQ514600A0 (https=)
BR (1) BR0107695A (https=)
CA (1) CA2397723C (https=)
CZ (1) CZ20022804A3 (https=)
DE (1) DE60139244D1 (https=)
HR (1) HRP20020593B1 (https=)
HU (1) HUP0301920A3 (https=)
IL (2) IL150548A0 (https=)
MX (1) MXPA02007004A (https=)
NO (1) NO329320B1 (https=)
NZ (2) NZ519990A (https=)
RU (1) RU2276996C2 (https=)
WO (1) WO2001052844A1 (https=)
YU (1) YU54702A (https=)
ZA (1) ZA200205715B (https=)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ514600A0 (en) 2000-01-18 2000-02-10 James Cook University Brain injury treatment
US20030083345A1 (en) * 2001-07-10 2003-05-01 Torsten Hoffmann Method of treatment and/or prevention of brain, spinal or nerve injury
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
SG168407A1 (en) 2003-01-28 2011-02-28 Ironwood Pharmaceuticals Inc Methods and compositions for the treatment of gastrointestinal disorders
GB0410215D0 (en) * 2004-05-07 2004-06-09 Lescroart Pol Nerve damage
CA2580694A1 (en) * 2004-09-23 2006-03-30 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
US20080045610A1 (en) * 2004-09-23 2008-02-21 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
JP2008531509A (ja) 2005-02-25 2008-08-14 エフ．ホフマン−ラ ロシュ アーゲー 医薬品成分の改良された分散性を有する錠剤
WO2006110118A1 (fr) * 2005-04-15 2006-10-19 Victor Pavlovich Kutnyak Produit cytoprotecteur
US20060239921A1 (en) 2005-04-26 2006-10-26 Novadaq Technologies Inc. Real time vascular imaging during solid organ transplant
US8185176B2 (en) 2005-04-26 2012-05-22 Novadaq Technologies, Inc. Method and apparatus for vasculature visualization with applications in neurosurgery and neurology
WO2007016790A1 (en) * 2005-08-10 2007-02-15 Novadaq Technologies, Inc. Intra-operative head & neck nerve mapping
US20070122344A1 (en) * 2005-09-02 2007-05-31 University Of Rochester Medical Center Office Of Technology Transfer Intraoperative determination of nerve location
US20070154448A1 (en) 2005-11-22 2007-07-05 Ted Reid Methods and compositions using Substance P to promote wound healing
US8945623B2 (en) * 2006-05-03 2015-02-03 Warsaw Orthopedic, Inc. Compositions comprising biomembrane sealing agent for treatment of neuronal injury, and methods of use
US20080161744A1 (en) * 2006-09-07 2008-07-03 University Of Rochester Medical Center Pre-And Intra-Operative Localization of Penile Sentinel Nodes
US20100086543A1 (en) * 2007-04-02 2010-04-08 Saint Louis University Compositions and methods for treating conditions associated with ceramide biosynthesis
US20080241121A1 (en) * 2007-04-02 2008-10-02 Daniela Salvemini Inhibitors of the ceramide metabolic pathway as adjuncts to opiates for pain
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2527360B1 (en) 2007-06-04 2015-10-28 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2009009829A1 (en) * 2007-07-19 2009-01-22 Adelaide Research & Innovation Pty Ltd Method for reducing intracranial pressure
US8406860B2 (en) 2008-01-25 2013-03-26 Novadaq Technologies Inc. Method for evaluating blush in myocardial tissue
US10219742B2 (en) 2008-04-14 2019-03-05 Novadaq Technologies ULC Locating and analyzing perforator flaps for plastic and reconstructive surgery
US20090263507A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Biological markers and response to treatment for pain, inflammation, neuronal or vascular injury and methods of use
EP2687235A3 (en) 2008-05-02 2014-11-05 Novadaq Technologies Inc. Methods for production and use of substance-loaded erythrocytes (S-LES) for observation and treatment of microvascular hemodynamics
EP2810951B1 (en) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP3241839B1 (en) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
SI2384318T1 (en) 2008-12-31 2018-03-30 Ardelyx, Inc. MEASURES AND PROCEDURES FOR THE INHIBITION OF ANTIPORT INHIBITED BY NHE IN THE TREATMENT OF DISEASES RELATED TO STRENGTH OF FLAMMABILITY OR TRADEMARITY WITH SOLO, AND THE EMISSION OF GASTROINTESTINAL TREATMENT
US8852566B2 (en) * 2009-03-26 2014-10-07 Warsaw Orthopedic, Inc. Compositions and methods for preferential distribution of active agents to injury sites
US10492671B2 (en) 2009-05-08 2019-12-03 Novadaq Technologies ULC Near infra red fluorescence imaging for visualization of blood vessels during endoscopic harvest
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
WO2012074043A1 (ja) * 2010-12-03 2012-06-07 国立大学法人 岡山大学 外傷性神経障害治療剤
WO2012125020A1 (en) * 2011-03-14 2012-09-20 N.V. Nutricia Method for treating neurotrauma
JP6028096B2 (ja) 2012-06-21 2016-11-16 ノバダック テクノロジーズ インコーポレイテッド 血管造影及びかん流の定量化並びに解析手法
MX366293B (es) 2012-08-21 2019-07-04 Ardelyx Inc Compuestos y metodos para inhibir al antipuerto mediado por nhe en el tratamiento de trastornos asociados con la retencion de fluidos o la sobrecarga de sal y trastornos del tracto gastrointestinal.
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
LT2983667T (lt) 2013-04-12 2019-07-10 Ardelyx, Inc. Nhe3 rišantys junginiai ir fosfato pernešimo slopinimo būdai
SI3004138T1 (sl) 2013-06-05 2024-07-31 Bausch Health Ireland Limited Ultra čisti agonisti gvanilat ciklaze C, postopek za njihovo pripravo in uporabo
CN105451727B (zh) * 2013-07-02 2019-04-23 尤斯特拉里斯制药有限公司（以普雷舒拉纽罗作为商号） 用于预防和/或治疗i型慢性创伤性脑病的方法
NZ714708A (en) * 2013-07-02 2019-06-28 Eustralis Pharmaceuticals Ltd Trading As Pressura Neuro Method for preventing and/or treating chronic traumatic encephalopathy-ii
US20160129007A1 (en) * 2013-07-02 2016-05-12 Eustralis Pharmaceuticals Limited (Trading As Pressura Neuro) Method for Preventing and/or Treating Chronic Traumatic Encephalopathy - IV
US20160136173A1 (en) * 2013-07-02 2016-05-19 Eustralis Pharmaceuticals Limited (Trading As Pressura Neuro) Method for Preventing and/or Treating Chronic Traumatic Encephalopathy - III
CN107209118B (zh) 2014-09-29 2021-05-28 史赛克欧洲运营有限公司 在自体荧光存在下生物材料中目标荧光团的成像
KR102012880B1 (ko) 2014-10-09 2019-08-22 노바다크 테크놀러지즈 유엘씨 형광-조정 광전용적맥파 측정기를 사용한 조직 내의 절대적인 혈류의 정량화
CA3049678A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds useful for treating gastrointestinal tract disorders
EA201991676A1 (ru) 2017-01-09 2020-01-30 Арделикс, Инк. Ингибиторы nhe-опосредованного антипорта
EP4242743A3 (en) 2017-02-10 2023-10-18 Stryker European Operations Limited Open-field handheld fluorescence imaging systems and methods
KR20220050956A (ko) * 2019-08-23 2022-04-25 유스트랄리스 파마슈티칼스 리미티드 (트레이딩 애즈 프레스수라 뉴로) 치료 방법 및 이의 용도
WO2021202286A1 (en) * 2020-03-30 2021-10-07 Dignify Therapeutics, Llc Compositions and methods for treating autonomic dysreflexia

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4481139A (en) * 1983-04-13 1984-11-06 Board Of Regents, The University Of Texas System Peptide antagonists of substance P
US4985896A (en) * 1985-03-29 1991-01-15 Canon Kabushiki Kaisha Laser driving device
GB8929070D0 (en) * 1989-12-22 1990-02-28 Fujisawa Pharmaceutical Co Peptide compounds,processes for preparation thereof and pharmaceutical composition comprising the same
US4981744A (en) * 1990-04-24 1991-01-01 Swank Michael W Non-planar expandable honeycomb structure
EP0655055B1 (en) * 1992-08-13 2000-11-29 Warner-Lambert Company Tachykinin antagonists
US5610165A (en) * 1994-02-17 1997-03-11 Merck & Co., Inc. N-acylpiperidine tachykinin antagonists
US5744482A (en) * 1994-10-05 1998-04-28 Eli Lilly And Company Serotonin agonist in combination with a tachykinin receptor antagonist in the treatment or prevention of migraine
US5998444A (en) * 1995-10-24 1999-12-07 Zeneca Ltd. Piperidinyl compounds as NK1 or NK2 antagonists
IL116249A (en) * 1994-12-12 2003-07-06 Pfizer Nk-1 receptor antagonists for the treatment of neuronal damage and stroke
WO1996024353A1 (en) * 1995-02-10 1996-08-15 Eli Lilly And Company Methods of treating or preventing psychiatric disorders
US5795894A (en) * 1995-05-02 1998-08-18 Schering Corporation Piperazino derivatives as neurokinn antagonists
US5990125A (en) 1996-01-19 1999-11-23 Pfizer Inc. NK-1 receptor antagonists for the treatment of cancer
WO1997038701A1 (en) * 1996-04-12 1997-10-23 Neotech Medical Innovations In Composition and method for the treatment of premenstrual syndrome
US5977104A (en) * 1996-12-02 1999-11-02 Merck Sharp & Dohme Ltd. Use of NK-1 receptor antagonists for treating bipolar disorders
JP2001513562A (ja) * 1997-08-28 2001-09-04 メルク エンド カムパニー インコーポレーテッド 月経前または黄体後期症候群の治療方法
GB9812662D0 (en) * 1998-06-11 1998-08-12 Merck Sharp & Dohme Therapeutic use
SI1157005T1 (en) 1999-02-24 2005-02-28 F. Hoffmann-La Roche Ag 3-phenylpyridine derivatives and their use as nk-1 receptor antagonists
HRP20010603A2 (en) 1999-02-24 2002-08-31 Hoffmann La Roche Phenyl-and pyridinyl derivatives
EP1394150B1 (en) 1999-02-24 2011-01-19 F. Hoffmann-La Roche AG 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists
US6291465B1 (en) 1999-03-09 2001-09-18 Hoffmann-La Roche Inc. Biphenyl derivatives
JO2308B1 (en) 1999-05-31 2005-09-12 اف. هوفمان- لاروش أيه جي‏ Derivatives of phenylpyrmidine
TW550258B (en) 1999-05-31 2003-09-01 Hoffmann La Roche 4-phenyl-pyrimidine derivatives
GB9923748D0 (en) 1999-10-07 1999-12-08 Glaxo Group Ltd Chemical compounds
AUPQ514600A0 (en) 2000-01-18 2000-02-10 James Cook University Brain injury treatment
US6479433B1 (en) * 2000-10-02 2002-11-12 Smithers-Oasis Company Polyurethane foam composites for grower applications and related methods

Also Published As

Publication number Publication date
RU2002121640A (ru) 2004-03-27
YU54702A (sh) 2006-01-16
US20050107380A1 (en) 2005-05-19
EP1261335A4 (en) 2004-09-22
EP1261335B1 (en) 2009-07-15
AUPQ514600A0 (en) 2000-02-10
NO329320B1 (no) 2010-09-27
AU782799B2 (en) 2005-09-01
US20180071333A1 (en) 2018-03-15
BR0107695A (pt) 2002-10-15
IL150548A0 (en) 2003-02-12
NZ534278A (en) 2005-08-26
JP4794794B2 (ja) 2011-10-19
MXPA02007004A (es) 2004-10-15
KR20020075784A (ko) 2002-10-05
HUP0301920A2 (hu) 2003-09-29
ZA200205715B (en) 2003-10-17
RU2276996C2 (ru) 2006-05-27
US6841551B2 (en) 2005-01-11
US20090253698A1 (en) 2009-10-08
EP1261335A1 (en) 2002-12-04
CA2397723A1 (en) 2001-07-26
NZ519990A (en) 2004-10-29
US20030109417A1 (en) 2003-06-12
DE60139244D1 (de) 2009-08-27
HK1054872A1 (en) 2003-12-19
WO2001052844A1 (en) 2001-07-26
JP2003520232A (ja) 2003-07-02
NO20023423D0 (no) 2002-07-17
CZ20022804A3 (cs) 2002-11-13
HUP0301920A3 (en) 2010-03-29
HRP20020593B1 (hr) 2011-03-31
US9186404B2 (en) 2015-11-17
US20160030474A1 (en) 2016-02-04
NO20023423L (no) 2002-09-16
AU2656001A (en) 2001-07-31
KR100780119B1 (ko) 2007-11-27
HRP20020593A2 (en) 2005-10-31
CA2397723C (en) 2010-08-31
PL358251A1 (en) 2004-08-09
US10201568B2 (en) 2019-02-12
IL150548A (en) 2011-05-31
CN1426302A (zh) 2003-06-25

Similar Documents

Publication Publication Date Title
CN1261095C (zh) 脑、脊髓和神经损伤治疗方法
RU2244558C2 (ru) Анестетическая композиция, включающая антагонист nmda и альфа-2 адренергический агонист
JP2024091801A (ja) 物質乱用の治療方法
AU2007221135A1 (en) Methods for regulating neurotransmitter systems by inducing counteradaptations
JP2011126909A (ja) エキソ−ｓ−メカミラミン製剤および治療におけるその使用
US20100173926A1 (en) Methods for Regulating Neurotransmitter Systems by Inducing Counteradaptations
CA2700477A1 (en) Method for reducing intracranial pressure
CN1121689A (zh) 吲哚衍生物作为5ht1拮抗剂的应用
KR20020068404A (ko) 미르타자핀을 포함하는, 우울증 및 관련 장애 치료용 약물조합물
CN101432011A (zh) 通过诱导逆适应调节神经递质系统的方法
RU2194505C2 (ru) Новое фармакологическое применение антагонистов а-ii рецептора
HUP0203466A2 (hu) Egy NK1 receptor antagonista és egy GABA szerkezeti analóg szinergikus kombinációja és ezt tartalmazó gyógyszerkészítmény és alkalmazása
HK1054872B (en) Brain, spinal and nerve injury treatment
CN1767833A (zh) 卡马西平衍生物在治疗痴呆患者的激动中的用途
CZ289344B6 (cs) Léčivo umoľňující pacientovi, aby sám omezil konzumaci alkoholu
DE60305018T2 (de) Citalopram zur behandlung von bluthochdruck
PL203468B1 (pl) Preparat do do zylnego lub domi esniowego leczenia uszkodzenia mózgu, rdzenia kr egowego i nerwów
Chaudhary et al. Pre-emptive Use of Oral Gabapentin and Pregabalin for Postoperative Analgesia in Lower Limb Surgery Under Spinal Anaesthesia: A Comparative Study

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20060628

Termination date: 20120118